A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
作者信息
Wassmann B, Gökbuget N, Scheuring U J, Binckebanck A, Reutzel R, Gschaidmeier H, Hoelzer D, Ottmann O G
机构信息
Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
出版信息
Ann Hematol. 2003 Nov;82(11):716-20. doi: 10.1007/s00277-003-0728-8. Epub 2003 Aug 28.
PMID:14648032
Abstract
摘要
Zotero 插件